About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.
Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).
Webcasts |
Recent Press Releases |
|
No current webcasts. MORE... |
Cardiome Discloses Chairman and CEO’s Involuntary Share Sale MORE... Cardiome Reports Third Quarter Results MORE... |
Disclaimer:
©2007 Stockgroup. Stockgroup Disclaimer. Quotes are provided by ComStock, Inc, a division of Interactive Data Corp. and are subject to their terms of use. Corporate and Financial Data is provided by CoreData. Data and information is provided for informational purposes only, and is not intended for trading purposes. Stockgroup shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Data is delayed 20 minutes for NYSE & AMEX and delayed 15 minutes for all other exchanges.